Madrigal ( (MDGL) ) has released its Q4 earnings. Here is a breakdown of the information Madrigal presented to its investors.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with significant unmet medical needs. The company’s flagship product, Rezdiffra, is the first FDA-approved treatment for MASH with moderate to advanced fibrosis.
In its latest earnings report, Madrigal Pharmaceuticals announced fourth-quarter and full-year 2024 financial results, highlighting the successful launch of Rezdiffra. The company reported net sales of $103.3 million for the fourth quarter and $180.1 million for the full year. Additionally, Madrigal shared promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, demonstrating Rezdiffra’s potential benefits in patients with compensated MASH cirrhosis.
Key financial metrics revealed that Madrigal’s operating expenses increased significantly due to commercial launch activities, resulting in a net loss of $465.9 million for the year. Despite this, the company maintained a strong cash position with $931.3 million in cash, cash equivalents, and marketable securities by year-end. The company also highlighted its strategic plans for European expansion and further indication expansion for Rezdiffra.
Looking ahead, Madrigal Pharmaceuticals is optimistic about its growth prospects, driven by the potential success of ongoing clinical trials and anticipated regulatory approvals in Europe. The company remains committed to advancing its leadership in the MASH treatment landscape and addressing the needs of patients with this serious liver condition.